Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26430873 | 0.98 | CA1 (0.37) | CA1CA2HSD17B10 | |
| SCHEMBL16333114 | 0.86 | TSHR (0.47) | CA1CA2CYP3A4TSHR | |
| SCHEMBL21634629 | 0.86 | ALDH1A1 (0.38) | TSHR | |
| SCHEMBL16140790 | 0.86 | ALDH1A1 (0.38) | TSHR | |
| SCHEMBL11602942 | 0.84 | TSHR (0.44) | CA1CA2CYP3A4TSHR | |
| SCHEMBL21987777 | 0.81 | CA2 (0.44) | CA2 | |
| SCHEMBL16051772 | 0.81 | CA2 (0.44) | CA2 | |
| SCHEMBL20624896 | 0.81 | CA2 (0.44) | CA2 | |
| SCHEMBL6279500 | 0.80 | — | — | |
| SCHEMBL4359971 | 0.77 | CA2 (0.40) | CA1CA2CYP3A4TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | CA1 4452/4885CA2 4531/4885CYP3A4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.